PLEASANTON, Calif. — NeoTract, Inc., today announced that Perito Urology in Coral Gables, Florida is the company’s first National Center of Excellence for training physicians on the UroLift® System implant procedure.
Dr. Paul Perito, a renowned expert in men’s health and sexual function, will conduct monthly education sessions consisting of didactic presentations, hands-on practice with the device and observation of multiple surgical cases for the attendees.
“The UroLift System is an exciting and unique treatment option for men suffering from an enlarged prostate.” said Paul Perito, MD. “I’m extremely thrilled to offer this technology at Perito Urology and train some of the country’s top urologists on this new implant procedure.”
“We are very pleased that Dr. Perito has partnered with us to educate and train his peers on our gamechanging technology.” stated Dave Amerson, President and CEO, NeoTract. “He is known as one of the world’s top urological surgeons focused on Men’s Sexual Health and is an ideal choice to launch our Center of Excellence training program in the U.S.”
Benign prostatic hyperplasia (BPH), also known as enlarged prostate, is a medical condition in which the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. The condition is common, affecting approximately 37 million men in the United States. BPH symptoms include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life. About one in four men experience BPH-related symptoms by age 55, with 90 percent of men over 70 symptomatic.
Medication is often the first line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra. While current surgical options, such as the ‘gold standard’ surgery, TURP, can be very effective in relieving symptoms, it can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).
The UroLift System permanent implants, delivered during a minimally-invasive procedure, effectively treat BPH by acting like window curtain tie-backs to hold the lobes of an enlarged prostate open. Patients recover from the procedure quickly, and return to their normal routines with minimal downtime. Most common adverse events reported from clinical studies include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. Learn more at www.UroLift.com.
NeoTract is dedicated to developing innovative, minimally-invasive and clinically-effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with benign prostatic hyperplasia (BPH) using the UroLift System, a minimally-invasive permanent implant system that treats symptoms while preserving normal sexual function. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.NeoTract.com.
Categorised in: Press Releases